Mismatch Repair Loss Renders ER+/HER2- Breast Cancer Susceptible to HER2/3 Inhibition

Abstract

The objective of this proposed study is to investigate a role for HER2/3 activation in MutLdefective ER breast cancer progression and resistance to endocrine therapy. By targeting HER2/3 signaling and key nodes of adaptive kinome response, we aim to significantly improve patient disease-specific survival.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Mar 01, 2019
Accession Number
AD1095864

Entities

People

  • Svasti Haricharan

Organizations

  • Sanford Burnham Prebys Medical Discovery Institute

Tags

DTIC Thesaurus Topics

  • African Americans
  • Biomedical Research
  • Breast Cancer
  • Cancer
  • Cells
  • Colon Cancer
  • Diseases And Disorders
  • Ethnic Groups
  • Growth Factors
  • Inhibition
  • Inhibitors
  • Mammary Glands
  • Medical Personnel
  • Neoplasms
  • Resistance
  • Standards
  • Targeting

Fields of Study

  • Medicine

Readers

  • Oncology
  • Oncology (Cancer Research).